Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

Gregory A. Wiseman, Christine A. White, Michael Stabin, William L. Dunn, William Erwin, Magnus Dahlbom, Andrew Raubitschek, Kastytis Karvelis, Timothy Schultheiss, Thomas E. Witzig, Richard Belanger, Stewart Spies, Daniel H.S. Silverman, Judy R. Berlfein, Eric Ding, Antonio J. Grillo-López

Research output: Contribution to journalArticle

215 Scopus citations

Abstract

Dosimetry studies in patients with non-Hodgkin's lymphoma were performed to estimate the radiation absorbed dose to normal organs and bone marrow from 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) treatment in this phase I/II, multicenter trial. The trial was designed to determine the dose of Rituximab (chimeric anti-CD20, Rituxan, IDEC-C2B8, MabThera), the unlabeled antibody given prior to the radioconjugate to clear peripheral blood B cells and optimize distribution, and to determine the maximum tolerated dose of 90Y-Zevalin [7.4, 11, or 15 MBq/kg (0.2, 0.3, or 0.4 mCi/kg)]. Patients received 111In-Zevalin (indium111 ibritumomab tiuxetan, IDEC-In2B8) on day 0 followed by a therapeutic dose of 90Y-Zevalin on day 7. Both doses were preceded by an infusion of the chimeric, unlabeled antibody Rituximab. Following administration of 111In-Zevalin, serial anterior/posterior whole-body scans were acquired. Major-organ radioactivity versus time estimates were calculated using regions of interest. Residence times were computed and entered into the MIRDOSE3 computer software program to calculate estimated radiation absorbed dose to each organ. Initial analyses of estimated radiation absorbed dose were completed at the clinical site. An additional, centralized dosimetry analysis was performed subsequently to provide a consistent analysis of data collected from the seven clinical sites. In all patients with dosimetry data (n=56), normal organ and red marrow radiation absorbed doses were estimated to be well under the protocol-defined upper limit of 20 Gy and 3 Gy, respectively. Median estimated radiation absorbed dose was 3.4 Gy to liver (range 1.2-7.8 Gy), 2.6 Gy to lungs (range 0.72-4.4 Gy), and 0.38 Gy to kidneys (range 0.07- 0.61 Gy). Median estimated tumor radiation absorbed dose was 17 Gy (range 5.8-67 Gy). No correlation was noted between hematologic toxicity and the following variables: red marrow radiation absorbed dose, blood T 1/2 , blood AUC plasma T 1/2 , and plasma AUC. It is concluded that 90Y. Zevalin administered at nonmyeloablative maximum tolerated doses results in acceptable radiation absorbed doses to normal organs. The only toxicity of note is hematologic and is not correlated to red marrow radiation absorbed dose estimates or T 1/2 , reflecting that hematologic toxicity is dependent on bone marrow reserve in this heavily pretreated population.

Original languageEnglish (US)
Pages (from-to)766-777
Number of pages12
JournalEuropean Journal of Nuclear Medicine
Volume27
Issue number7
DOIs
StatePublished - 2000

Keywords

  • Dosimetry
  • IDEC- Y2B8
  • Non-Hodgkin's lymphoma
  • Radioimmunotherapy
  • Rituximab
  • Yttrium 90 Zevalin

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Phase I/II <sup>90</sup>Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Wiseman, G. A., White, C. A., Stabin, M., Dunn, W. L., Erwin, W., Dahlbom, M., Raubitschek, A., Karvelis, K., Schultheiss, T., Witzig, T. E., Belanger, R., Spies, S., Silverman, D. H. S., Berlfein, J. R., Ding, E., & Grillo-López, A. J. (2000). Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. European Journal of Nuclear Medicine, 27(7), 766-777. https://doi.org/10.1007/s002590000276